Navigation Links
Immune Design Corp. Announces Appointment of Dr. Bruce L.A. Carter as Executive Chairman and Director
Date:11/23/2009

SEATTLE, Nov. 23 /PRNewswire/ -- Immune Design Corp. (IDC) announced today that Dr. Bruce L.A. Carter has joined IDC as Executive Chairman. Dr. Carter has a successful track record in biotechnology executive management. He was the former Chief Executive Officer at ZymoGenetics, in Seattle, WA and Chief Scientific Officer at Novo Nordisk, Copenhagen, Denmark.

(Photo: http://www.newscom.com/cgi-bin/prnh/20091123/SF15228)

Dr. Steven Reed, IDC's founder and Chief Executive Officer commented, "I am delighted to welcome Dr. Bruce Carter as a new member of IDC's management team and Board of Directors. His appointment and his broad biotech experience signifies our commitment to building a strong company that delivers on its scientific objectives. He is a great addition to IDC."

"With Dr. Steven Reed's expertise on vaccine adjuvants and Dr. David Baltimore's and Dr. Thomas Dubensky's expertise on the lentivirus-based vectors to introduce antigens to dendritic cells, IDC is poised to develop new improved vaccines to a world that desperately needs them," said Dr. Carter.

Dr. Carter possesses a unique combination of strong leadership skills and technical expertise in progressing healthcare products from the bench to the clinic, and ultimately to the people who need them.

Dr. Carter currently serves on the Board of ZymoGenetics, Dr. Reddy's Laboratories, the Hyderabad, India based generic drug maker, QLT, Inc. Vancouver, Canada and the nonprofit Global Alliance TB Drug Development Board, New York, NY. He joins IDC after a long career in the biotechnology and pharmaceutical arena.

Dr. Carter began his career in drug discovery at G. D. Searle. In 1986, he was appointed as V.P. and Head of Research & Development at ZymoGenetics. In 1994 he became a Corporate Executive V.P. at Novo Nordisk, as well as Chief Scientific Officer. In 2000, Dr. Carter led the negotiations that established ZymoGenetics as an independent company from Novo Nordisk and he became the CEO transforming the company from the research arm of a European company to a company that developed and commercialized Recothrom®.

IDC - Innovative Science

IDC's goal is to develop and commercialize new safe and effective vaccine products to prevent or target infectious and malignant diseases. IDC utilizes proprietary Toll-like receptor-4 agonist adjuvant and lentivirus-based vector platforms, which both target dendritic cells and are used to deliver antigens together with desired immunostimulatory signals.

For more information, go to www.immunedesign.com.


Contact:

Cassie Ostrander 206-826-7901 or
cassie.ostrander@immunedesign.com

SOURCE Immune Design Corp.


'/>"/>
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. CEL-SCI Collaborators Present Data Suggesting That LEAPS Technology Has Ability to Modify Immune Response
2. RNL BIO Rescues a College Student from Autoimmune Hearing Loss
3. MedImmune Highlights Inflammatory Disease Portfolio at 73rd Annual Meeting of the American College of Rheumatology
4. Peptimmune to Collaborate on Dengue Virus Vaccine and Point-Of-Care Diagnostic With Two DOD Biomedical Research Facilities
5. Octapharma Aims to Expand U.S. Immune Globulin Therapy Portfolio
6. Rib-X Pharmaceuticals, Inc. Appoints Tony Zook of MedImmune to Board of Directors
7. MarketsandMarkets: Global Autoimmune Treatment Market Worth US$68.81 Billion by 2014
8. Peptimmune Completes Phase Ib Study of PI-2301 in Multiple Sclerosis Patients, and Presentation at ECTRIMS 2009
9. Fast Forward, LLC and Amplimmune, Inc. Join Forces to Speed New Treatments to People with MS**
10. AutoImmune Inc. Reports 2009 Second Quarter Financial Results
11. Transposagen Creates a Rat Model of the Human Immune System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of commercial spectrophotometers and ... and the 6000i models are higher end machines that use the more unconventional z-dimension ... light beam from the bottom of the cuvette holder. , FireflySci has developed ...
(Date:6/23/2016)... , ... June 23, 2016 , ... ... release of its second eBook, “Clinical Trials Patient Recruitment and Retention Tips.” Partnering ... retention in this eBook by providing practical tips, tools, and strategies for clinical ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
Breaking Biology Technology:
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:6/1/2016)... NEW YORK , June 1, 2016 ... Biometric Technology in Election Administration and Criminal Identification to ... According to a recently released TechSci Research report, " ... Sector, By Region, Competition Forecast and Opportunities, 2011 - ... $ 24.8 billion by 2021, on account of growing ...
(Date:5/16/2016)... NEW YORK , May 16, 2016   ... authentication solutions, today announced the opening of an IoT ... to strengthen and expand the development of embedded ... provides an unprecedented level of convenience and security with ... to authenticate one,s identity aside from DNA. EyeLock,s platform ...
Breaking Biology News(10 mins):